As Canada advances toward National Pharmacare and recalibrates its drug pricing and reimbursement frameworks, the country's senior market access leaders will gather to address the most consequential policy shifts in a generation at the 11th Annual Forum on Pathways to Access & Reimbursement, March 25–26, 2026, in Toronto.

Hosted by the Canadian Institute, the forum brings together pharmaceutical manufacturers, provincial payers, federal policymakers, health economists, and patient access professionals to navigate an increasingly complex reimbursement landscape shaped by PMPRB reform, rare disease frameworks, and rising demands for real-world evidence and health equity.

In his official welcome message, Premier of Ontario Doug Ford emphasized the forum's importance: “Conferences like this bring together key stakeholders—government leaders, advocates, healthcare providers, pharmaceutical manufacturers—to examine ways to improve patient access and outcomes. It’s an opportunity for meaningful discussions regarding innovation solutions”.

Practical Strategy for a Shifting Policy Environment 

Designed specifically for the Canadian pharmaceutical market, the forum moves beyond high-level discussion to deliver actionable intelligence on pricing strategy, launch sequencing, payer negotiations, and evidence generation in today's access climate.

Key topics include:

• National Pharmacare & PMPRB reform: Implications for launch sequencing, pricing strategy, and negotiation
• Federal–provincial alignment: Navigating jurisdictional complexity in access and reimbursement
• Rare disease & high-impact therapies: Lessons from real-world access pathways
• Data-driven access: Leveraging HEOR, RWE, and predictive analytics to support decisions and improve equity

Cross-Sector Collaboration Driving Solutions

The 2026 program features decision-makers from industry, government, patient advocacy, health economics, and public affairs, fostering the dialogue necessary to move from policy debate to implementation.

"The stakes have never been higher for market access professionals," said Ilda Cordeiro, the Conference Producer. "Between National Pharmacare implementation, evolving provincial formularies, and new expectations around value demonstration, we're operating in a fundamentally different environment. This forum is where the sector comes together to decode what's working, what's changing, and how to succeed in 2026 and beyond."

Confirmed participating organizations include:

Alexion Pharmaceuticals | ALS Canada | AstraZeneca | BC Ministry of Health | Bioscience Association Manitoba | Canadian CML Network | Canadian Organization for Rare Disorders | ClaimSecure | Connex Health | Global Public Affairs | Hoffmann-La Roche | IQVIA | Myeloma Canada | Patented Medicine Prices Review Board | Patient Voice Partners | Sandoz Canada | UCB Canada | and more.

***

Event Details:

11th Annual Forum on Pathways to Access & Reimbursement

March 25–26, 2026 | Toronto, ON

Registration and program: https://www.canadianinstitute.com/pathways-access-reimbursement/